Table 5.
Association of various clinical factors with overall response to hypomethylating therapy.
| Variables | Any Response to HMT | |
|---|---|---|
| Odds Ratio (95% CI) | p-Value a | |
| TET2 mutation | 0.900 (0.148–5.489) | 0.909 |
| High miR-22 expression | 1.548 (0.261–9.175) | 0.631 |
| IPSS (higher-risk to lower-risk disease) b | 2.222 (0.377–13.082) | 0.377 |
| IPSS-R (higher-risk to lower-risk disease) b | 1.689 (0.327–8.732) | 0.532 |
| Cytogenetic abnormality | 4.200 (0.454–38.843) | 0.206 |
| Cytogenetic risk categories | 1.846 (0.193–17.700) | 0.595 |
| (higher-risk to lower-risk karyotype) c | ||
| Poor-risk gene mutation | 0.933 (0.180–4.838) | 0.935 |
| Elderly (≥70) | 0.933 (0.180–4.838) | 0.935 |
Abbreviations: CI, confidence interval; HMT, hypomethylating therapy; IPSS, International Prognostic Scoring System; IPSS-R, Revised International Prognostic Scoring System; TET2, Tet methylcytosine dioxygenase 2. a p-value was calculated via univariate logistic regression analysis. b Based on the IPSS and IPSS-R, patients are divided into lower-risk disease (IPSS low, intermediate-1; IPSS-R very low, low, intermediate) and higher-risk disease (IPSS Intermediate-2, high; IPSS-R high, very high) groups. c Based on the IPSS-R, cytogenetic risk categories are divided into lower-risk karyotype (IPSS-R very good, good) and higher-risk karyotype (IPSS-R intermediate, poor, very poor).